Loren C Denlinger1,2, Tonya S King3, Juan Carlos Cardet4, Timothy Craig3, Fernando Holguin5,6, Daniel J Jackson1,2, Monica Kraft7, Stephen P Peters8, Kristie Ross9, Kaharu Sumino10, Homer A Boushey11, Nizar N Jarjour1,2, Michael E Wechsler12, Sally E Wenzel5,6, Mario Castro10, Pedro C Avila13. 1. 1 Department of Medicine and. 2. 2 Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 3. 3 Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania. 4. 4 Department of Medicine, Brigham & Women's Hospital, Boston, Massachusetts. 5. 5 Department of Pediatrics and. 6. 6 Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 7. 7 Department of Medicine, Duke University School of Medicine, Durham, North Carolina. 8. 8 Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina. 9. 9 Department of Pediatrics, Rainbow Babies & Children's Hospital, Cleveland, Ohio. 10. 10 Department of Medicine, Washington University in St. Louis, St. Louis, Missouri. 11. 11 Department of Medicine, University of California San Francisco, San Francisco, California. 12. 12 Department of Medicine, National Jewish Health, Denver, Colorado; and. 13. 13 Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Abstract
RATIONALE: Restoration of vitamin D sufficiency may reduce asthma exacerbations, events that are often associated with respiratory tract infections and cold symptoms. OBJECTIVES: To determine whether vitamin D supplementation reduces cold symptom occurrence and severity in adults with mild to moderate asthma and vitamin D insufficiency. METHODS: Colds were assessed in the AsthmaNet VIDA (Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness) trial, in which 408 adult patients were randomized to receive placebo or cholecalciferol (100,000 IU load plus 4,000 IU/d) for 28 weeks as add-on therapy. The primary outcome was cold symptom severity, which was assessed using daily scores on the 21-item Wisconsin Upper Respiratory Symptom Survey. MEASUREMENTS AND MAIN RESULTS: A total of 203 participants experienced at least one cold. Despite achieving 25-hydroxyvitamin D levels of 41.9 ng/ml (95% confidence interval [CI], 40.1-43.7 ng/ml) by 12 weeks, vitamin D supplementation had no effect on the primary outcome: the average peak WURSS-21 scores (62.0 [95% CI, 55.1-68.9; placebo] and 58.7 [95% CI, 52.4-65.0; vitamin D]; P = 0.39). The rate of colds did not differ between groups (rate ratio [RR], 1.2; 95% CI, 0.9-1.5); however, among African Americans, those receiving vitamin D versus placebo had an increased rate of colds (RR, 1.7; 95% CI, 1.1-2.7; P = 0.02). This was also observed in a responder analysis of all subjects achieving vitamin D sufficiency, regardless of treatment assignment (RR, 1.4; 95% CI, 1.1-1.7; P = 0.009). CONCLUSIONS: Our findings in patients with mild to moderate asthma undergoing aninhaled corticosteroid dose reduction do not support the use of vitamin D supplementation for the purpose of reducing cold severity or frequency.
RCT Entities:
RATIONALE: Restoration of vitamin D sufficiency may reduce asthma exacerbations, events that are often associated with respiratory tract infections and cold symptoms. OBJECTIVES: To determine whether vitamin D supplementation reduces cold symptom occurrence and severity in adults with mild to moderate asthma and vitamin Dinsufficiency. METHODS: Colds were assessed in the AsthmaNet VIDA (Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness) trial, in which 408 adult patients were randomized to receive placebo or cholecalciferol (100,000 IU load plus 4,000 IU/d) for 28 weeks as add-on therapy. The primary outcome was cold symptom severity, which was assessed using daily scores on the 21-item Wisconsin Upper Respiratory Symptom Survey. MEASUREMENTS AND MAIN RESULTS: A total of 203 participants experienced at least one cold. Despite achieving 25-hydroxyvitamin D levels of 41.9 ng/ml (95% confidence interval [CI], 40.1-43.7 ng/ml) by 12 weeks, vitamin D supplementation had no effect on the primary outcome: the average peak WURSS-21 scores (62.0 [95% CI, 55.1-68.9; placebo] and 58.7 [95% CI, 52.4-65.0; vitamin D]; P = 0.39). The rate of colds did not differ between groups (rate ratio [RR], 1.2; 95% CI, 0.9-1.5); however, among African Americans, those receiving vitamin D versus placebo had an increased rate of colds (RR, 1.7; 95% CI, 1.1-2.7; P = 0.02). This was also observed in a responder analysis of all subjects achieving vitamin D sufficiency, regardless of treatment assignment (RR, 1.4; 95% CI, 1.1-1.7; P = 0.009). CONCLUSIONS: Our findings in patients with mild to moderate asthma undergoing an inhaled corticosteroid dose reduction do not support the use of vitamin D supplementation for the purpose of reducing cold severity or frequency.
Entities:
Keywords:
WURSS-21; asthma; upper respiratory tract infection; vitamin D
Authors: Carlos A Camargo; Tristram Ingham; Kristin Wickens; Ravi Thadhani; Karen M Silvers; Michael J Epton; G Ian Town; Philip K Pattemore; Janice A Espinola; Julian Crane Journal: Pediatrics Date: 2010-12-27 Impact factor: 7.124
Authors: Loren C Denlinger; Ron L Sorkness; Wai-Ming Lee; Michael D Evans; Michele J Wolff; Sameer K Mathur; Gina M Crisafi; Katie L Gaworski; Tressa E Pappas; Rose F Vrtis; Elizabeth A Kelly; James E Gern; Nizar N Jarjour Journal: Am J Respir Crit Care Med Date: 2011-11-01 Impact factor: 21.405
Authors: David R Murdoch; Sandy Slow; Stephen T Chambers; Lance C Jennings; Alistair W Stewart; Patricia C Priest; Christopher M Florkowski; John H Livesey; Carlos A Camargo; Robert Scragg Journal: JAMA Date: 2012-10-03 Impact factor: 56.272
Authors: Carlos A Camargo; Davaasambuu Ganmaa; A Lindsay Frazier; Franca F Kirchberg; Jennifer J Stuart; Ken Kleinman; Nyamjav Sumberzul; Janet W Rich-Edwards Journal: Pediatrics Date: 2012-08-20 Impact factor: 7.124
Authors: Sif Hansdottir; Martha M Monick; Sara L Hinde; Nina Lovan; Dwight C Look; Gary W Hunninghake Journal: J Immunol Date: 2008-11-15 Impact factor: 5.422
Authors: Michael Schatz; Mark Kosinski; Aaron S Yarlas; Jennifer Hanlon; Maria E Watson; Priti Jhingran Journal: J Allergy Clin Immunol Date: 2009-09-19 Impact factor: 10.793
Authors: M J Walter; M Castro; S J Kunselman; V M Chinchilli; M Reno; T P Ramkumar; P C Avila; H A Boushey; B T Ameredes; E R Bleecker; W J Calhoun; R M Cherniack; T J Craig; L C Denlinger; E Israel; J V Fahy; N N Jarjour; M Kraft; S C Lazarus; R F Lemanske; R J Martin; S P Peters; J W Ramsdell; C A Sorkness; E R Sutherland; S J Szefler; S I Wasserman; M E Wechsler Journal: Eur Respir J Date: 2008-09-03 Impact factor: 16.671
Authors: Adrian R Martineau; Christopher J Cates; Mitsuyoshi Urashima; Megan Jensen; Alex P Griffiths; Ulugbek Nurmatov; Aziz Sheikh; Chris J Griffiths Journal: Cochrane Database Syst Rev Date: 2016-09-05
Authors: Manish P Ponda; Yupu Liang; Jaehwan Kim; Richard Hutt; Kathleen Dowd; Patricia Gilleaudeau; Mary M Sullivan-Whalen; Tori Rodrick; Dong Joo Kim; Irina Barash; Michelle A Lowes; Jan L Breslow Journal: Am J Clin Nutr Date: 2017-02-22 Impact factor: 7.045
Authors: Margaret T Lee; Meyer Kattan; Ilene Fennoy; Stephen M Arpadi; Rachel L Miller; Serge Cremers; Donald J McMahon; Jeri W Nieves; Gary M Brittenham Journal: Blood Adv Date: 2018-05-08
Authors: Katarzyna Ostrzyżek-Przeździecka; Mariusz Panczyk; Aleksandra Ratajczak; Michał Bronikowski; Wojciech Feleszko Journal: Health Qual Life Outcomes Date: 2021-05-24 Impact factor: 3.186
Authors: Matthew C Altman; Avraham Beigelman; Christina Ciaccio; James E Gern; Peter W Heymann; Daniel J Jackson; Joshua L Kennedy; Kirsten Kloepfer; Robert F Lemanske; Laurie M McWilliams; Lyndsey Muehling; Christy Nance; R Stokes Peebles Journal: J Allergy Clin Immunol Date: 2020-01-09 Impact factor: 14.290